Editas Medicine (EDIT) Non-Current Deffered Revenue (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Non-Current Deffered Revenue data on file, last reported at $44.5 million in Q4 2025.

• Non-Current Deffered Revenue for Q4 2025 came in at $44.5 million, down 17.89% year-over-year; the trailing twelve-month figure through Dec 2025 was $44.5 million (down 17.89% YoY), and the FY2025 annual result was $44.5 million, down 17.89% from the prior year.
• Non-Current Deffered Revenue eased to $44.5 million in Q4 2025 per EDIT's latest filing, from $54.2 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $68.9 million in Q2 2022 and troughed at $44.5 million in Q4 2025.
• A 5-year average of $57.8 million and a median of $58.7 million in 2021 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2021 and 2022: Non-Current Deffered Revenue tumbled 60.1% in 2021, then climbed 24.75% in 2022.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $60.9 million in 2021, then fell by 0.36% to $60.7 million in 2022, then changed by 0.0% to $60.7 million in 2023, then declined by 10.65% to $54.2 million in 2024, then dropped by 17.89% to $44.5 million in 2025.
• Business Quant data shows EDIT's Non-Current Deffered Revenue at $44.5 million in Q4 2025, $54.2 million in Q3 2025, and $54.2 million in Q2 2025.